Fuji Photo Film Company, Limited

Kabushiki Kaisha Toshiba

Fujifilm Corporation

Other

Toshiba Medical Systems Corporation

Ihara, Masataka

Kozo Sato

Hiroyuki Hirai

Yoshiharu Yabuki

Ken Kawata

Hideki Naito

Hiroshi Hara

Hiroshi Kitaguchi

Masaaki Tsukase

Yoshio Ishii

Masatoshi Kato

Masashi Takeuchi

Toshiaki Aono

Katsuyoshi Yamakawa

Yasuhiro Shimada

Shinsaku Fujita

Toru Harada

Ken Iwakura

Makoto Suzuki

Koichi Nakamura

Akira Igarashi

Takeshi Shibata

Soichiro Yamamoto

Tadahisa Sato

Shigehide Kuhara

Shoichi Kanayama

Seiiti Kubodera

Koushin Matsuoka

Toshimitsu Sakuma

Osamu Takahashi

Kiyoshi Takeuchi

Toshiki Taguchi

Hisashi Mikoshiba

Hideaki Naruse

Masato Satomura

Toshio Kawagishi

Shigeki Uehira

Jiro Tsukahara

Sadao Ishige

Mariko Shibata

Toshihide Yoshitani

Takeshi Nakamine

Masayuki Kawakami

Hajime Kato

Masayoshi Tsuboi

Shigeru Yamazaki

Masataka Ihara

Khanitha Pudhom

Kiyosei Takasu

Takashi Suginome

Takeshi Murakami

Shigeru Ohno

Kazunobu Katoh

Yasuhiro Yoshioka

Keisuke Shiba

Satoru Ohishi

Koki Nakamura

Kazuya Okamoto

Naoki Saito

Yu Zou

Taku Nakamura

Satoshi Aida

Yasuo Mukunoki

Yuki Mizukawa

Takuji Suzuki

Isamu Itoh

Katsuyuki Watanabe

Shintaro Washizu

Osamu Uchida

Yoshisada Nakamura

Keiji Takeda

Michael D Silver

Sumito Yamada

Katsuhiko Fujimoto

Jun Yamaguchi

Akira Ikeda

Takehiko Sato

Fumio Mogi

Keizo Koya

Takafumi Hosokawa

Motoji Haragashira

Koichi Koyama

Yoshiharu Ishibashi

Shunichi Ishikawa

Yoichi Takada

Hiroyuki Naito

Kiyotaka Fukagawa

Ayao Itoh

Masaru Ukai

Yukihiko Sakaguchi

Yasutoshi Ishihara

Yasuhiro Aiki

Koshin Matsuoka

Yoshihide Hayakawa

Masasi Takeuchi

Hideaki Okami

Kanitha Pudhom

Provided are a method for manufacturing a chlorogenic acid-containing composition, including a chlorogenic acid extraction step of obtaining a chlorogenic acid-containing liquid extract from sunflower seed residues remaining after oil expression by bringing chlorogenic acid and saccharides derived from the sunflower seed residues remaining after oil expression into contact with yeast and a solvent selected from the group consisting of water, an alcohol, and a liquid mixture of water and an alcohol, and a bacterial treatment step of performing at least one treatment selected from germicidal treatment or sterilization treatment on the liquid extract, a chlorogenic acid-containing composition obtained by the manufacturing method, and a drink or food item containing the chlorogenic acid-containing composition.

Chlorogenic acid-containing composition, method for manufacturing same, and drink or food item

Provided are a method for manufacturing 3,4,5-tricaffeoylquinic acid, which can produce 3,4,5-tricaffeoylquinic acid with high efficiency by a simple operation in a short process using inexpensive raw materials, and intermediate compounds. The method for manufacturing 3,4,5-tricaffeoylquinic acid of the invention includes at least Step (1) of allowing a compound represented by Formula (1) or a compound represented by Formula (2) to react with a compound represented by Formula (4); and Step (2) of deprotecting the product obtained in Step (1), and producing 3,4,5-tricaffeoylquinic acid: 

Method for manufacturing 3,4,5-tricaffeoylquinic acid

Provided is a polyester polymer including a repeating unit derived from a dicarboxylic acid compound containing a partial structure represented by the following Formula (C) and a repeating unit derived from a diol compound containing a cyclic structure, in which the partial structure represented by Formula (C) constitutes a portion of the main chain: 

Polyester polymer, resin composition, molded product, and film

Provided is a dehydroabietic acid polymer including a skeleton of the following formula (A) as a repeating unit: wherein L represents a divalent organic group. Methods for producing the dehydroabietic acid polymer are also provided. The dehydroabietic acid polymer has high resistance against moisture and water and high impact resistance. The dehydroabietic acid polymer can also be produced from a rosin-derived natural product.

Dehydroabietic acid polymer, compact, method for producing dehydroabietic acid polymer, and dehydroabietic acid compound

A patient terminal can communicate with doctor terminals and a center terminal via a communication network. The patient terminal acquires vital data from a measuring device with a receiving unit. A control unit determines whether the vital data contains an abnormal value and the necessity of messaging depending on the presence or absence of a manual messaging request with a message button and selects the doctor terminal or the center terminal. When it is determined that messaging is necessary, the control unit makes a communication unit call the selected terminal.

Method, apparatus and system for providing healthcare support by message based communication to healthcare support terminals

Provided is a polyamide polymer in which a partial structure represented by the following formula (C) constitutes a portion of the main chain: 

Polyamide polymer, method for producing same, resin composition, molded product, fiber, film, and porous film

The present invention is to provide a medicinal composition for preventing or treating parasitic protozoan infections, having a high selective toxicity against parasitic protozoan infection, and a superior preventive or treating effect. A medicinal composition for preventing or treating parasitic protozoan infections comprises a compound shown by the following general formula (1) as an active ingredient (wherein R represents an alkyl group, aryl group or heterocyclic group; A and B each independently represents a 5- or 6-membered ring containing at least one hetero atom, or a condensation ring wherein 1 or more 3- to 8-membered ring is condensed thereto; Y represents S, O, Se, or &#x2014;NR&#x2014; (Rrepresents an alkyl group, aryl group or heterocyclic group); L, L, L, Land Leach independently represents a methine group; Q represents a physiologically acceptable anion; k represents an integer of 0 to 2, necessary to make the electric charge of the whole molecule 0; p and q each represents an integer of 0 to 3, wherein the sum of p and q is 1 or more, and 6 or less).

Medicinal composition for prevention or treatment of parasitic protozoan infection

Scattered radiation is estimated by using a reduced image generated from a projection image, and the scattered radiation image of the projection image is acquired by enlargement processing. The scattered radiation correction of the projection image is executed by subtracting the obtained scattered radiation image from the projection image. In addition, when a primary X-ray image and a scattered radiation image in each projection direction are to be obtained by sequential approximation calculation, a primary X-ray image which has already been identified in an adjacent projection direction is used as a first estimated value (initially set value) in next sequential calculation.

Scattered radiation correction method and scattered radiation correction apparatus

The present invention is to provide an anti-trypanosomiasis agent having a high selective toxicity, and high preventing or treating effect against trypanosomiasis, comprising a compound shown by the following general formula (1) as an active ingredient (wherein Rand Reach independently represents a hydrogen atom, halogen atom, hydroxyl group, oxygen atom, Calkyl group, Calkoxy group, Caryl group, Caryloxy group, Calkoxycarbonyl group or Calkylaminocarbonyl group, and may be bound to each other; R, R, and Reach independently represents a Calkyl group or Caryl group; Rand Reach independently represents a hydrogen atom, halogen atom, hydroxyl group, oxygen atom, Calkyl group, Calkoxy group, Caryl group, Caryloxy group, or Calkoxycarbonyl group, and may be bound to each other; Y and Z each independently represents an atom group necessary to form a 5- or 6-membered heterocycle; m and n each represent 0 or 1; Q represents a physiologically acceptable anion; k represents an integer of 0 to 2, necessary to make the electric charge of the whole molecule 0).

Anti-trypanosomiasis agent

Silver halide color photographic light-sensitive material

The present invention provides a silver halide photographic light-sensitive material comprising a support having thereon at least one layer comprising at least one compound represented by the following general formula (1): ##STR1## thereby providing a silver halide photographic light-sensitive material containing a developing agent which can effect color developing reaction efficiently with a known coupler without being restricted by the kind of the coupler.

Silver halide photographic light-sensitive material

The object is to provide a silver halide photographic light-sensitive material containing a developing agent which can effect color developing reaction efficiently with a known coupler without being restricted by the kind of the coupler. Namely, the present invention is a silver halide photographic light-sensitive material comprising a support having thereon at least one layer comprising at least one compound represented by the following general formula (1): ##STR1## wherein, R.sub.1 to R.sub.4 represent a hydrogen atom or substituent, A represents a hydroxyl group or substituted amino group, X represents a di- or higher valent connecting group selected from --CO--, --SO--, --SO.sub.2 -- and --PO&lt;, Y represents a bivalent connecting group, Z represents a group which is nucleophilic and can attack X when the present compound is oxidized, and R.sub.1 and R.sub.2, and R.sub.3 and R.sub.4 may be linked each other to form a ring, respectively.

A silver halide color photographic light-sensitive material comprising a support having provided thereon at least one silver halide emulsion layer, wherein the silver halide color photographic light-sensitive material contains at least one dye forming coupler represented by the following formula (I): ##STR1## wherein R.sub.1 represents a substituted or unsubstituted aliphatic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted aryloxy group, a substituted or unsubstituted alkylthio group, a substituted or unsubstituted arylthio group or a substituted or unsubstituted amino group; X.dbd.Y represents C.dbd.O, C.dbd.NR.sub.2, P.dbd.O or S.dbd.O; R.sub.2 represents an aliphatic group or an aromatic group; Z represents a group capable of being released upon a reaction with the oxidation product of a developing agent; m and n each represents an integer of 1 or 2; R.sub.1 and R.sub.2, R.sub.1 and Z or R.sub.2 and Z may be combined with each other to form a ring; and when m is 2, two R.sub.1 's may be the same or different, or may be combined with each other to form a ring. The dye forming coupler represented by the formula (I) provides a yellow dye having excellent hue, a large molecular extinction coefficient and storage stability, and the silver halide color photographic light-sensitive material containing the yellow dye forming coupler is excellent in color reproducibility, sharpness and color image fastness.

A silver halide color photographic material is disclosed which contains at least one 1H-pyrrolo�1,2-c!�1,2,3!triazole based dye-forming coupler represented by the following formula: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 each represents a hydrogen atom or a substituent; and X represents a hydrogen atom or a group capable of being released upon reaction with the oxidation product of a color developing agent.

Silver halide color photographic material

A nuclear magnetic resonance imaging scheme capable of reducing the eddy currents induced within the living body outside of the imaging region, so as to protect the patient against the nerve stimulation due to the eddy currents, and obtaining the MR images at high image quality by protecting the image quality against the N/2 and chemical artifacts. The nerve stimulation is prevented by providing a shield member for shielding a nerve stimulation sensitive portion of the patient located outside of the imaging region from a change of the gradient magnetic fields. The artifacts are prevented by applying a reading gradient magnetic field which is repeatedly switching its polarity along a phase encoding gradient magnetic field applied at a rate of once in every two switchings of the reading gradient magnetic field, separating the acquired NMR signals resulting from odd and even turns of switchings of the reading gradient magnetic field as separate data sets, and re-constructing MR images from the separate data set for odd turns and even turns separately.

Nuclear magnetic resonance imaging with protection against artifacts

Growing community of inventors

Kanagawa, Japan

Kozo Sato